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Background: Several genotyping protocols have been described to study Candida albicans strains with different
sensitivity values. In this study we have analyzed the genetic relatedness and the antifungal susceptibility of several
Candida albicans strains isolated from a patient who from suffered recurrent candiduria for a period of five years.
Strains were genotyped using Microsatellite Length Polymorphism (MLP) with three microsatellite markers (HIS 3,
EF 3 and CDC 3), and a new method based on high resolution melting (HRM) was developed to analyze the
microsatellite region. This method was compared with the conventional technique that uses capillary
electrophoresis.
Results: MICs of the isolates showed the existence of fluconazole susceptible and resistant strains. An inter-colony
test using single concentration (8 and 16 mg/l) of fluconazole revealed the coexistence of both fluconazole
susceptible and resistant strains. Both genotyping analysis methods showed that all the patient’s isolates had a
clonal origin. HRM analysis method developed was able to accurately establish strain relatedness and presented a
discriminatory power of 0.77.
Conclusions: Although HRM analysis method presented a lower discriminatory power compared to methods
based on capillary electrophoresis, it provided a more cost-effective and suitable alternative for genotyping C.
albicans in a clinical laboratory.
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Candida albicans is a ubiquitous commensal in healthy
individuals; it is, however, a very important opportunistic
pathogen for immunologically weak and immuno-
compromised people [1]. Recurrent and/or persistent
infections by Candida species are frequent, particularly
in oropharyngeal and vaginal candidiasis, although it has
also been described in urinary tract infections [2]. Stud-
ies describing recurrent infections have focused on de-
termining the relatedness between colonizing and
infective strains [3,4], as well as between successive in-
fective strains [5-9]. It seems clear now that the majority
of commensal and infecting populations of C. albicans* Correspondence: buitrago@isciii.es
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reproduction in any medium, provided the orfrom the same individuals are clonal in origin but subse-
quently undergo microevolution at the site of colonization
and through recurrent episodes of infection [5,10,11]. The
microevolution of the strains is a frequent process in re-
current infections and it takes place in response to adap-
tive changes [9,12]. A recent work which examined the
“in vitro” dynamics of C. albicans populations in the pres-
ence or absence of fluconazole has shown that mutations
that lead to increased drug resistance appear frequently
[13]. Others authors suggest that natural C. albicans
populations comprise a mixture of closely related strain
types [6].
Typing methods have been described as useful tools for the
differentiation between strains isolated only once and those
able to cause recurrent infections. Although several typing
methods have been described for C. albicans (AFLP, RFLP-
PCR or MLST), one of the most suitable is the fragment
length analysis of microsatellites called Microsatellite Lengthtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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atory power and reproducibility. MLP analysis has proved its
efficacy and reproducibility in a large number of epidemio-
logical studies [9,14-19]; however, this technique is not easy to
use and the estimated cost per isolate remains high.
The High Resolution Melting (HRM) provides a faster and
cheaper method for microsatellite fragment analysis. This
technique uses fluorescent DNA binding dyes with improved
saturation properties allowing a precise assessment of se-
quence variation based on DNA melting curves analysis
[20,21]. The suitability of HRM to discriminate PCR products
based on one nucleotide change has also been described.
Some recent articles, focusing on the capacity of HRM to
identify and genotype fungi, have been reported [15,22].
In this work, we developed a method based on HRM
to assess the relatedness of strains in a clinical case of
recurrent candiduria. The results were compared with
the conventional MLP genotyping techniques. The iso-
lates, recovered over a period of five years, additionally
showed significant differences in their susceptibility to
antifungal agents. Antifungal susceptibility test and se-
lection of resistant population was performed.
Methods
Origin of the strains and clinical data from the patient
The strains were isolated from a 62 year old male with
medullary sponge right kidney (Carchi-Ricci disease) andTable 1 MICs values and isolation data of the clinical isolates
Strain Isolate origin Isolation data AB 5FZ
CNM-CL-4929 Blood culture 02-28-2003 0.03 0.12
L06/31 Urine 02-01-2006 0.12 0.12
L06/32 Urine 02-01-2006 0.12 0.12
CNM-CL-6188# Urine 08-18-2006 0.25 0.12
L06/260 Urine 08-18-2006 0.06 0.12
L06/349 Urine 11-07-2006 0.06 0.12
L06/350 Urine 11-07-2006 0.06 0.12
CNM-CL-6361# Urine 03-20-2006 0.25 0.12
CNM-CL-6373# Urine 04-16-2006 0.12 0.12
L07/130 Urine 04-16-2006 0.12 128
CNM-CL-6399# Urine 05-21-2007 0.25 0.12
CNM-CL-6431# Urine 06-13-2007 0.25 0.12
CNM-CL-6488# Urine 07-27-2007 0.12 0.12
L07/453 Urine 11-21-2007 0.03 0.12
L07/454 Urine 11-21-2007 0.03 0.12
CNM-CL-6714# Urine 03-07-2008 0.25 0.12
CNM-CL-7019# Urine 11-12-2008 0.12 0.12
CNM-CL-7020# Urine 11-12-2008 0.25 0.12
# Strains included in the genotyping analysis.
* No MICs data available.
CNM-CL Yeast Collection of the Spanish National Center for Microbiology.recurrent reno-urethral lithiasis subjected to several litho-
tripsies. The patient was admitted in a Tertiary General
Hospital (Hospital Virgen de la Concha, Zamora, Spain)
diagnosed with right pyelonephritis caused by obstructive
kidney stones. C. albicans was isolated in blood cultures
and urocultures. The antifungal susceptibility profile
showed that azoles and amphotericin B were active in vitro
against this strain (CNM-CL-4929, Yeast Collection of the
Spanish National Centre for Microbiology) as shown in
Table 1.
Treatment with ciprofloxacin 400 mg/12 h and flucona-
zole iv 200 mg/12 h was started. After three days of treat-
ment, as fever persisted and blood and urine cultures
remained positive, fluconazole was replaced by amphoteri-
cin B lipid complex 200 mg/24 h iv and 100 mg every other
day. Six days after admission, lithotripsy was performed
and a double J stent was placed. He was discharged from
hospital a month after admission. From 2003 to 2008, the
patient suffered from several episodes of Candida infection
and underwent multiple lithotripsies. He was treated with
oral fluconazole (200 mg/12 h) several times. A total of 18
strains were isolated from urine and sent to the Mycology
Reference Laboratory for identification and susceptibility
testing (Table 1). In 2006 the susceptibility of one of the iso-
lates (CNM-CL-6188) showed high MICs for fluconazole
(>8 mg/l). Three months later, the patient was readmitted
to the hospital and diagnosed with hydronephrosis andused in this study
FZ IZ VZ PZ CA MC AN
0.12 0.015 0.015 * * * *
0.5 0.015 0.015 0.015 0.03 0.03 0.03
0.5 0.015 0.015 0.015 0.03 0.03 0.03
> 64 > 8 > 8 > 8 0.25 0.03 0.03
8 1 0.12 1 0.03 0.03 0.03
0.25 0.015 0.015 0.015 0.12 0.03 0.03
0.25 0.015 0.015 0.015 0.12 0.03 0.03
> 64 > 8 > 8 > 8 0.25 0.03 0.03 #
> 64 1 > 8 4 0.25 0.03 0.03
16 16 16 16 0.25 0.03 0.03
> 64 > 8 > 8 > 8 0.25 0.03 0.03 #
> 64 > 8 > 8 > 8 0.25 0.03 0.03 #
0.25 0.015 0.015 0.015 0.25 0.03 0.03 #
0.12 0.015 0.015 0.015 0.12 0.03 0.03
0.25 0.06 0.06 0.12 0.06 0.03 0.03
> 64 0.06 > 8 > 8 0.25 0.03 0.03 #
2 0.12 0.015 0.06 0.25 0.03 0.03 #
0.25 0.015 0.015 0.015 0.25 0.03 0.03 #
Table 2 Intercolony fluconazole susceptibility in single
concentration microdilution plates
No of colonies fluconazole resistant










CNM-CL Yeast Collection of the Spanish National Center for Microbiology.
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in the right kidney. The stent was removed and a percutan-
eous nephrostomy was performed. An initial treatment
with caspofungin 70 mg iv and then 50 mg iv/24 h was
established. Later, the patient was treated with amphoteri-
cin B lipid complex (11 days) and was subsequently put
back on caspofungin until patient was discharged from the
hospital. During the stay in the hospital, blood cultures
were negative while urine cultures remained positive until
the patient was treated with amphotericin B. The patient’s
isolates were controlled in an outpatient mode up to the
end of 2008, at which time the patient went to another in-
stitution and no more samples were taken. The written
informed consent was sought and obtained from the pa-
tient according to Spanish regulations at that date. The pa-
tient also signed his consent to the release of his clinical
and personal information in a scientific publication.
Antifungal susceptibility testing
Antifungal susceptibilities were tested in vitro according
to the EUCAST microdilution method (AFST-EUCAST,
definitive document 7.1). Interpretative breakpoints pro-
posed by EUCAST for fluconazole and voriconazole
were used [23]. For the rest of the antifungal tested, the
breakpoints proposed by Rodriguez-Tudela et al. were
used [24]. The antifungal agents used were amphotericin
B, flucytosine, fluconazole, itraconazole, voriconazole,
posaconazole, caspofungin, micafungin, and anidulafun-
gin. Isolates were stored at −20°C until use.
Selection of resistant population
In February of 2011, the isolates available in our culture
collection (Tables 1 and 2) were subcultured for genotyping
studies. To analyze the probability of the coexistence of
fluconazole resistant and susceptible populations in each
isolate, we performed a screening assay based on a single-
concentration fluconazole test [25]. The antifungal concen-
tration used in this assay was selected on the basis of the
MIC values previously obtained. The test of growth was
performed in microplates containing RPMI 1640 medium
supplemented with 2% glucose (Sigma-Aldrich, Madrid,
Spain) and a final fluconazole concentration of 8 and
16 mg/l. Ten colonies of each isolate were tested. For each
colony, a suspension of 105 cfu/ml was prepared. Plates
were inoculated with 0.1 ml from the cell suspension. A
growth control was also included. The Optical Density
(OD) at 530 nm was measured after 24 and 48 hours of in-
cubation. The reduction of the OD below 50% compared to
control was considered as susceptibility to fluconazole.
Genotyping studies
Nine representative strains isolated from the patient on
different days were selected for performance of genotyp-
ing studies (Tables 1 and 3). The control populationconsisted of 20 strains from patients geographically and
temporally unrelated. Nineteen out of 20 isolates were
from whole blood and the remaining isolate was from
pleural fluid (Table 3). ATCC64548 and ATCC64550 C.
albicans reference strains were also included in this
study. All isolates were identified by physiological and
morphological tests, including microscopic examination
and biochemical tests. The identification was confirmed
by sequence analysis of the ITS (internal transcribed
spacer) region of the rDNA [26].
Yeast cells were grown for 24 hours in Sabouraud broth
medium at 30°C. Genomic DNA was extracted using a
phenol:chloroform method [27] followed by purification
using Chroma SPIN +TE 400 columns according to the
manufacturer’s instructions (Clontech Laboratories, Becton
Dickinson, Madrid, Spain).
Genotyping analysis of C. albicans was performed using
MLP procedure with three different markers previously
described, CDC 3 [28]; EF 3 [29] and HIS 3 [30]. The pri-
mers sequences used to amplify these markers were: CDC3
forward (50 CAGATGATTTTTTGTATGAGAAGAA30) and
reverse (50 CAGTCACAAGATTAAAATGTTCAAG30); EF3
forward (5 TTTCCTCTTCCTTTCATATAGAA30) and re-
verse (5 GGATTCACTAGCAGCAGACA30) and HIS3 for-
ward (5 TGGCAAAAATGATATTCCAA30) and reverse
(50 TACACTATGCCCCAAACACA 30).
MLP analysis using capillary electrophoresis was
modified from Botterel et al. [14]. Alleles were amplified
in a multiplex PCR in a 50 μl final volume containing
20 ng DNA, 1X PCR-Buffer II (Applied Biosystems, Ma-
drid, Spain), 0.2 mM of each deoxynucleotide triphos-
phate, 5 mM of MgCl2, and 0.15 μM of each primer and
1U of AmpliTaq Polymerase (Applied Biosystems).
Sense CDC3 primer was labelled with 4, 7, 20, 40, 50, 70-
hexachloro-6-carboxyfluorescein (HEX), EF3 antisense
primer with 6-carboxyfluorescein (FAM) and HIS 3
Table 3 Microsatellite lenght (bp) for the three microsatellite markers using capillary electrophoresis
Strain Isolateorigin
Length (bp) determined by PCR analysis of microsatellite markers:
CDC 3 EF 3 HIS 3
CNM-CL-7426a Whole blood 117/125 125/125 162/186
CNM-CL-7449a Whole blood 117/125 125/125 162/190
CNM-CL-7470a Whole blood 117/125 120/120 162/227
CNM-CL-7471a Whole blood 117/117 130/130 162/162
CNM-CL-7478a Whole blood 117/125 120/120 202/202
CNM-CL-7484a Whole blood 125/125 125/125 162/190
CNM-CL-7498a Whole blood 125/129 130/139 149/166
CNM-CL-7499a Whole blood 117/129 130/139 154/154
CNM-CL-7503a Whole blood 117/117 126/138 153/182
CNM-CL-7504a Whole blood 117/117 124/130 149/166
CNM-CL-7513a Whole blood 121/125 124/137 158/158
CNM-CL-7617a Whole blood 117/117 124/130 313/313
CNM-CL-7624a Whole blood 117/117 126/138 153/153
CNM-CL-7620a Whole blood 117/125 120/120 162/210
CNM-CL-7640a Whole blood 125/129 130/137 149/166
CNM-CL-7643a Pleural fluid 117/117 124/130 149/166
CNM-CL-7683a Whole blood 117/125 120/129 162/210
CNM-CL-7694a Whole blood 117/129 130/139 148/153
CNM-CL-7705a Whole blood 117/117 124/130 —/—
CNM-CL-7712a Whole blood 117/125 120/129 162/210
ATCC64548a Whole blood 113/113 124/124 162/162
ATCC64550a Whole blood 117/125 120/129 162/178
CNM-CL-6188b Urine 121/121 127/129 153/153
CNM-CL-6361b Urine 121/121 127/129 153/153
CNM-CL-6373b Urine 121/121 127/129 153/153
CNM-CL-6399b Urine 121/121 127/129 153/153
CNM-CL-6431b Urine 121/121 127/129 153/153
CNM-CL-6488b Urine 121/121 127/129 153/153
CNM-CL-6714b Urine 121/121 127/129 153/153
CNM-CL-7019b Urine 121/121 127/129 153/153
CNM-CL-7020b Urine 121/121 127/129 153/153
CNM-CL Yeast Collection of the Spanish National Center for Microbiology.
a: Control population.
b: strains from the case study included for genotyping studies.
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fused phenyl-1.4-dichloro-6-carboxyfluorescein (NED).
Primers were synthesized by Sigma-Aldrich (Sigma-
Aldrich, Madrid, Spain).
PCR reactions were performed in a GeneAmp PCR
system 9700 (Applied Biosystems). The cycling condi-
tions included a first step for preincubation (activation
of the enzyme) and denaturation of the DNA template
at 95°C during 5 minutes. Next steps consisted in an
amplification program of 30 cycles as follow: denatur-
ation at 95°C for 30 s, annealing at 55°C for 30 s andextension at 72°C for 1 min with a final extension step
of 7 min at 72°C.
To assess the size of the fragments, 1 μl of the PCR
products was added to 9 μl of Formamide Hi-Di
(Applied Biosystems, Madrid, Spain) and 1 μl of the in-
ternal size standard ROX 500 (Applied Biosystems, Madrid,
Spain). Capillary electrophoresis was run using the ABI
3730 XL (Applied Biosystems, Madrid, Spain) sequencer.
Fragment size for the different alleles was calculated with
GeneMapper version 3.0 (Applied Biosystems, Madrid,
Spain).
Figure 1 (See legend on next page.)
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Figure 1 Difference plots for the normalized and temperature shifted melting curves for microsatellite from control population and
patient strains. A) CDC3 marker; B) EF3 marker and C) HIS3 marker.
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using singleplex PCRs with each pair of primers without
any modification of the reaction conditions. Control
population was selected based on MLP results. Strains
included as control were: CL 7484, CL 7498, CL 7504,
CL 7513, CL 7694, ATCC 64548 and ATCC 64550 (Fig-
ure 1). Seven different genotypes for the three markers
were chosen (Figure 1).
After PCR, HRM analysis was performed in a LightCycler
480 system (Roche, Madrid, Spain). To obtain the HRM
curves, 1 μl of LightCyclerW 480 ResoLight Dye (Roche,
Madrid, Spain) was added to PCR products and the reac-
tions were incubated at 95°C 1 min, followed by a renatura-
tion step of 40°C for 1 min. Melting curves were generated
by ramping from 65° to 95° at 0.02°C/s, 25 acquisitions/°C.
HRM curves were plotted using the automated grouping
option provided by the software and by manual editing for
each microsatellite marker. Normalization conditions for
each microsatellite marker are shown in Table 4.
For sequencing, amplicons were treated with ExoSap –
IT (GE Health Care, Madrid, Spain) following the manu-
facturer’s instructions. Sequencing reactions were per-
formed in a GeneAmp PCR system 9700 (Applied
Biosystems). Sequences were analyzed in triplicate.
The numerical index of discriminatory power for each
marker and for the multiplex analysis was calculated in
both genotyping analysis using the Simpson biodiversity
index (D) [31]. The percentage of heterozygosis has been
calculated by the ratio number of heterozygous geno-
types/ total number of genotypes.Results
Antifungal susceptibility testing
Antifungal susceptibility results are shown in Table 1. At
first, isolates were susceptible to all antifungal agents
tested; however, in August 2006 an isolate showed an
azole-resistant phenotype and subsequently isolates sus-
ceptible and resistant to azoles appeared at random. Be-
tween March 2006 and June 2007 all strains tested were
azole-resistant but this pattern changed again betweenTable 4 High resolution melting conditions and discriminatio
HRM Marker Pre-Melt T Post-Me
CDC 3 71.95-72.96 79.34-81.
EF 3 70.8-72.62 78.46-79.
HIS 3 68.65-69.82 77.42-78.
MultiplexJuly and November 2007. The latest azole resistant strain
recovered was from March 2008.
Fluconazole resistance selection
Ten colonies of each of the nine isolates genotyped were
tested for fluconazole resistance at 8 and 16 mg/l final
concentration. From five out of the 9 strains we were
able to select resistant and susceptible isolates. On the
other hand, from one strain all colonies were resistant
and from the remaining three strains all checked col-
onies were susceptible to fluconazole in a final concen-
tration of 8 mg/l. When fluconazole concentration was
increased to 16 mg/l, the number of resistant colonies
was reduced (Table 2).
Genotyping studies
Microsatellite length genotyping
Microsatellite markers were used to genotype the nine
strains recovered from the patient. Each PCR product
was assigned to an allele [14] so each strain was charac-
terized by 6 alleles that were differently coupled
(Table 3). Strains from the patient showed the same
microsatellite pattern for the three markers and they
were different from the control population (Table 3). All
the isolates recovered from the patient were homozy-
gous for CDC 3 and HIS 3 markers while they showed a
heterozygous genotype for EF 3 (Table 5).
The D value for EF3 was 0.86, similar to that previ-
ously reported [14,15], for CDC 3 it was 0.81, and for
HIS 3 it was 0.87. The combination of three markers
yielded a discriminatory power of 0.92 (Table 5).
Microsatellite HRM genotyping
When analysis by HRM was performed, isolates from
the patient were grouped together for the three markers
analyzed (Figure 1).
The analysis of marker CDC 3 showed that all homo-
zygous strains, including those from the patient, were
plotted in one group except for the CNM- CL 7020
strain (Figure 1A). Due to the unexpected result for
CNM-CL7020, the PCR product was sequenced (6xn power





Table 5 Characteristics of the microsatellite loci analyzed by capillary electrophoresis
Microsatellite Marker No. of alleles No. of genotypes No. of heterozygotic genotypes DP % heterozygosity
CDC 3 5 8 4 0.81 50.00
EF 3 10 11 7 0.86 63.63
HIS 3 14 15 11 0.88 53.30
Multiplex 0.92
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the forward primer was found. Heterozygous strains
were distributed in four groups according to their frag-
ment length. The heterozygous strains CNM-CL 7694
and ATCC 64550 were plotted together although one of
the alleles were different (Table 3). When we performed
EF 3 fragments analysis by HRM, six different groups
were plotted one of them contained strains from the pa-
tient while the control population was distributed into
five groups according to its fragment size or whether
they were homozygous or heterozygous (Figure 1B).
Finally, HRM analysis of the HIS3 marker showed six
different groups. Strains from the patient were grouped
together again. Strains in the control population were
grouped based on their fragment size pattern (Figure 1C).
Discrimination power for CDC 3 marker was 0.53, for
EF 3 it was 0.62 and for the HIS 3 marker it was 0.68.
The combination of the three markers provided a DP
value of 0.77 (Table 4).
Discussion
Typing methods have been described as useful tools for
the differentiation between strains isolated only once
and those able to cause recurrent infections. Several
methods have been developed to analyze microevolution
and structure of C. albicans species. Although MLST
(MultiLocus Sequence Typing) has been chosen as the
most discriminatory technique [5,32], several articles
have recently pointed towards the suitability of MLP
[14-16,29]. In this study, nine isolates from a case of re-
current urinary infection were genotyped using microsa-
tellites and a new HRM analysis method. Antifungal
susceptibility testing revealed that strains from the
patient were susceptible and resistant in vitro to flucona-
zole in a random way. Microvariation between colonies
due to exposure of C. albicans to azole antifungal agents
has been widely described [10,16] and the need to perform
intercolony assays has also been reported [25,33,34]. We
performed an inter-colony test modified from Schoofs
et al. [25] and we were able to prove the coexistence of
colonies resistant and susceptible to azoles in a high num-
ber of the strains tested. The number of azole-resistant
colonies was variable depending on azole concentration.
A genotyping method based on HRM analysis was
developed taking into account previous works showing
that if the number of genotypes is higher than seven, thecurve definition is not the best possible [35]. Based on that
premise, for each marker we selected seven strains with
different genotype, previously analysed by capillary elec-
trophoresis. C. albicans microsatellites (CDC3, EF3 and
HIS3) were amplified using LightCyclerW 480 ResoLight
as intercalating dye. When HRM analysis was performed,
the isolates from the patient were plotted together and
these results were consistent with those obtained by capil-
lary electrophoresis. There was only one exception for the
CDC3 marker where one strain (CNM-CL7020) was not
grouped, as expected, with the other strains showing the
same MLP genotype. The sequence of the fragment
showed a 3 bp insertion that explained the melting differ-
ences. This fact supports previous works in which HRM
allowed to identify changes in the sequence length and
one nucleotide changes [36].
Although the calculated discrimination power was
higher for the analysis using capillary electrophoresis
than for HRM analysis (0.92 vs. 0.77) as previously
reported [14]. The HRM analysis showed several advan-
tages; it was a very simple and fast technique and results
were obtained in 3 hours (including amplification), the
interpretation of results was easy and the cost per sam-
ple was much lower than MLP genotyping due to this
technique does not require sequencing equipment and
the primers are not end-labelled. Our estimate is that
the cost per sample using capillary electrophoresis is
more than twice that of using HRM analysis. Further-
more, it can be used in a routine laboratory setting as it
only requires real time PCR equipment. In this study, al-
though we were not able to demonstrate the mechanism
underlying the variability in the susceptibility to azoles
in the strains tested, we were able to confirm that resist-
ant and susceptible isolates were genetically closely
related with an easy method to analyze microsatellites.
The results highlight the need for more in-depth studies
to be performed on these kinds of infections for an ac-
curate and appropriate management thereof.
Conclusions
This method is a useful tool for performing a fast
screening to establish relatedness between strains in out-
breaks or surveillance studies in cases of recurrent or
persistent infections. To our knowledge, this is the first
study in which three microsatellite markers were ana-
lyzed by HRM by using seven strains with different
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lution limits. Although HRM analysis method presented
a lower degree of discrimination compared to other
genotyping methods, it provided a more cost-effective
and suitable alternative for genotyping C. albicans in a
clinical laboratory.
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